CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy

被引：3

作者：

Mu, Yeteng ^{[1
,2
]}

Guan, Xingang ^{[1
]}

机构：

[1] Taizhou Univ, Sch Med, Dept Basic Med, Taizhoum 318000, Zhejiang, Peoples R China

[2] Beihua Univ, Sch Med Technol, Jilin 132013, Jilin, Peoples R China

来源：

CURRENT MEDICINAL CHEMISTRY | 2024年 / 31卷 / 13期

关键词：

TIGIT; CD155; PD-1; immune checkpoint inhibitor; cancer immunotherapy; tumor cells; CD8(+) T-CELLS; NECTIN-LIKE PROTEINS; GROWTH-FACTOR; TIGIT; MELANOMA; BLOCKADE; RECEPTOR; DNAM-1; PD-1; EXPRESSION;

D O I：

10.2174/0929867330666230324152532

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Immune checkpoint inhibitors (ICIs) have shown unprecedented efficacy in treating many advanced cancers. Although FDA-approved ICIs have shown promising efficacy in treating many advanced cancers, their application is greatly limited by the low response rate, immune-related adverse events (irAE), and drug resistance. Developing novel ICIs holds great promise to improve the survival and prognosis of advanced cancer patients. T-Cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on T cells, natural killer (NK) cells, and T regulatory cells. Increasing reports have shown that the disrupting CD155-TIGIT axis could activate the immune system and restore antitumor immune response. This review briefly summarized the role of TIGIT in tumor immune escape and targeting CD155-TIGIT axis drugs in preclinical and clinical trials for cancer immunotherapy.

引用

页码：1634 / 1645

页数：12

共 50 条

[41] Prognostic Relevance of Immunosuppressive CD155/TIGIT Signaling in Locally Advanced Rectal Cancer Patients With Neoadjuvant Chemoradiotherapy [J].

Tsai, Yuan-yao ;

Ke, Tao-wei ;

Huang, Chi-hsien ;

Chen, Tsung-wei ;

Lin, Yu-sen ;

Chen, Te-hong ;

Chen, Hui-yu ;

Chen, William tzu-liang ;

Chao, K. s. clifford ;

Huang, Kevin chih-yang .

ANTICANCER RESEARCH, 2025, 45 (01) :323-333

[42] Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer [J].

Liu, Lu ;

Wang, Aihong ;

Liu, Xiaoli ;

Han, Sai ;

Sun, Yu ;

Zhang, Junhua ;

Guo, Lingyu ;

Zhang, Youzhong .

JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)

[43] CD6 is a target for cancer immunotherapy [J].

Ruth, Jeffrey H. ;

Gurrea-Rubio, Mikel ;

Athukorala, Kalana S. ;

Rasmussen, Stephanie M. ;

Weber, Daniel P. ;

Randon, Peggy M. ;

Gedert, Rosemary J. ;

Lind, Matthew E. ;

Amin, M. Asif ;

Campbell, Phillip L. ;

Tsou, Pei-Suen ;

Mao-Draayer, Yang ;

Wu, Qi ;

Lanigan, Thomas M. ;

Keshamouni, Venkateshwar G. ;

Singer, Nora G. ;

Lin, Feng ;

Fox, David A. .

JCI INSIGHT, 2021, 6 (05)

[44] Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma [J].

Wu, Lei ;

Mao, Liang ;

Liu, Jian-Feng ;

Chen, Lei ;

Yu, Guang-Tao ;

Yang, Lei-Lei ;

Wu, Hao ;

Bu, Lin-Lin ;

Kulkarni, Ashok B. ;

Zhang, Wen-Feng ;

Sun, Zhi-Jun .

CANCER IMMUNOLOGY RESEARCH, 2019, 7 (10) :1700-1713

[45] Blockade of the TIGIT-CD155/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia [J].

Seel, Katharina ;

Schirrmann, Ronja Larissa ;

Stowitschek, Daniel ;

Ioseliani, Tamar ;

Roiter, Lea ;

Knierim, Alina ;

Andre, Maya C. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (09)

[46] Targeting TIGIT for cancer immunotherapy: recent advances and future directions [J].

Peng Zhang ;

Xinyuan Liu ;

Zhuoyu Gu ;

Zhongxing Jiang ;

Song Zhao ;

Yongping Song ;

Jifeng Yu .

Biomarker Research, 12

[47] Targeting TIGIT for cancer immunotherapy: recent advances and future directions [J].

Zhang, Peng ;

Liu, Xinyuan ;

Gu, Zhuoyu ;

Jiang, Zhongxing ;

Zhao, Song ;

Song, Yongping ;

Yu, Jifeng .

BIOMARKER RESEARCH, 2024, 12 (01)

[48] CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer [J].

Catalan, Rodrigo ;

Orozco-Morales, Mario ;

Hernandez-Pedro, Norma Y. ;

Guijosa, Alberto ;

Colin-Gonzalez, Ana L. ;

avila-Moreno, Federico ;

Arrieta, Oscar .

JOURNAL OF IMMUNOLOGY RESEARCH, 2020, 2020

[49] CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer [J].

Li, Yuchen ;

Gu, Yinfeng ;

Yang, Pengyue ;

Wang, Yan ;

Yu, Xibao ;

Li, Yangqiu ;

Jin, Zhenyi ;

Xu, Ling .

IMMUNOTARGETS AND THERAPY, 2024, 13 :1-14

[50] Targeting immunotherapy for bladder cancer by using anti-CD3 x CD155 bispecific antibody [J].

Ma, Wanru ;

Ma, Juan ;

Lei, Ting ;

Zhao, Man ;

Zhang, Man .

JOURNAL OF CANCER, 2019, 10 (21) :5153-5161

← 1 2 3 4 5 →